论文部分内容阅读
目的:观察新辅助化疗联合应用参附注射液在治疗头颈鳞癌中的疗效和毒副作用。方法:将44例头颈鳞癌患者随机分成2组,参附联合化疗组行参附注射液联合化疗,单纯化疗组行单纯化疗,就其临床疗效、毒副作用进行对比研究。结果:两组病员新辅助化疗疗效(χ2=0.014,P>0.05)、治疗前后体质量(t=2.018,P>0.05)及心脏毒性(χ2=0.516,P>0.05)均未见显著性差异。而参附注射液联合化疗组在改善KPS评分(χ2=4.207,P<0.05)、减轻骨髓毒性(χ2=4.385,P<0.05)方面较单纯化疗组有显著性差异(P<0.05)。结论:在头颈鳞癌新辅助化疗中联合参附注射液能减轻化疗药物毒副作用、提高患者的生活质量。
Objective: To observe the efficacy and side effects of neoadjuvant chemotherapy combined with Shenfu injection in the treatment of head and neck squamous cell carcinoma. Methods: Forty-four patients with squamous cell carcinoma of the head and neck were randomly divided into two groups. The treatment group was treated with combination of chemotherapy with ginseng and ginseng combined with chemotherapy. The chemotherapy alone group was treated with chemotherapy alone. The clinical efficacy and side effects were compared. Results: There was no significant difference between the two groups in neoadjuvant chemotherapy (χ2 = 0.014, P> 0.05), body mass (t = 2.018, P> 0.05) and cardiotoxicity . However, Shenfu injection combined with chemotherapy group had significant difference (P <0.05) in improving KPS score (χ2 = 4.207, P <0.05) and alleviating myelotoxicity (χ2 = 4.385, P <0.05) Conclusion: The combination of Shenfu injection with neoadjuvant chemotherapy for head and neck squamous cell carcinoma can reduce the side effects of chemotherapy drugs and improve the quality of life of patients.